Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 209

The DOI matches its Crossref record.

Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer ( Mycobacterium ulcerans Disease)

Open access
Chauty, Annick, Ardant, Marie-Françoise, Adeye, Ambroise, Euverte, Hélène, Guédénon, Augustin, Johnson, Christian, Aubry, Jacques, Nuermberger, Eric, Grosset, Jacques·2007·Antimicrobial Agents and Chemotherapy

Abstract

According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and streptomycin, administered daily for 8 weeks, was recommended to 310 patients diagnosed with Buruli ulcer in Pobè, Bénin. Among the 224 (72%) eligible patients for whom treatment was initiated, 215 (96%) were categorized as treatment successes, and 9, including 1 death and 8 losses to follow-up, were treatment failures. Of the 215 successfully treated patients, 102 (47%) were treated exclusively with antibiotics and 113 (53%) were treated with antibiotics plus surgical excision and skin grafting. The size of lesions at treatment initiation was the major factor associated with surgical intervention: 73% of patients with lesions of >15 cm in diameter underwent surgery, whereas only 17% of patients with lesions of <5 cm had surgery. No patient discontinued therapy for side effects from the antibiotic treatment. One year after stopping treatment, 208 of the 215 patients were actively retrieved to assess the long-term therapeutic results: 3 (1.44%) of the 208 retrieved patients had recurrence of Mycobacterium ulcerans disease, 2 among the 107 patients treated only with antibiotics and 1 among the 108 patients treated with antibiotics plus surgery. We conclude that the WHO-recommended streptomycin-rifampin combination is highly efficacious for treating M. ulcerans disease. Chemotherapy alone was successful in achieving cure in 47% of cases and was particularly effective against ulcers of less than 5 cm in diameter.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.00175-07

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 209

Metadata

Authors
Chauty, A., Ardant, M.-F., Adeye, A., Euverte, H., Guédénon, A., Johnson, C., Aubry, J., Nuermberger, E., & Grosset, J.
Venue
Antimicrobial Agents and Chemotherapy
Published
2007-11
Volume
51
Issue
11
Pages
4029-4035
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2066311301
Cited by
209
References
0
FWCI
12.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer ( Mycobacterium ulcerans Disease). https://app.cochat.ai/papers/10.1128/aac.00175-07
The paper
Chauty, A., Ardant, M.-F., Adeye, A., Euverte, H., Guédénon, A., Johnson, C., Aubry, J., Nuermberger, E., & Grosset, J. (2007). Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer ( Mycobacterium ulcerans Disease). Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00175-07

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.